It wont be Labor Day because AW will not have been here long enough, and the FDA's decision will be too close to Labor Day to let Sanofi decide what they are going to do. It will not be just the Multaq team if 55C and AW have any good sense, it will be all teams in the company. I would guess it will be all teams affected by layoffs again during Sanofi's favorite time of year at Thanksgiving.
Still need CV for Plavix and they are buying or co-marketing a drug and rumor of the MS drug going to CV so I dont see CV going friends. Not being unrealistic Plavix is still in the bag and now it may take longer than September for the FDA to sort this mess out.
The only thing is that the MS drug is going to neurology only, along with the other 4 new MS drugs launched within the last year by different companies. I have 5 Neurology clinics in my territory. This is not enough to keep two Multaq reps per territory.
MS sales forces are typically small. 300 reps is a high number in this space. Sanofi may decide they need a higher share of voice by the time the oral launches, but that won't be sustainable for long. If they were smart (I think we know the answer to that), they would poach other ms reps with relationships.
I'm going with the first week in December. The old, "stay home & wait for the call the Monday after Thanksgiving." CV is done. Even if we do get the Neuro product, it's a bigger dog than Multaq. Check out the side effect profile. It's going to be a non factor in the market. Diabetes is so overstaffed right now, there is no way they can take anybody else. The Specialty Reps are tripping over themselves & calling on a ton of Primary Care Targets now because they don't have enough specialists to see. The Primary Care Reps are going out of their minds because they're calling on targets with 0 value. Now they add more reps to sell Apidra??? Terrible business model & destined to fail as soon as they start seeing that we're not growing or making money. My prediction: CV - 300+ reps after Thanksgiving. Diabetes - Major restructure to align to the business.
could not agree with you more. i wonder how much they'll cut mtin because we are responsible for less than ten percent of lantus sales and even less for apidra with hardly any hospitals buying it.
